Aims/Purpose: Alzheimer's disease (AD) is the most prevalent form of dementia and remains a pressing concern in our society with an ageing population. Increasing evidences suggest a link between brain damage and retinal ganglion cell (RGC) loss opening new paradigm to diagnose this condition using the eye as a window to the brain. Curcumin is a natural polyphenol with neuroprotective properties but a low bioavailability preventing its use as a potential treatment in AD. The goal of this research was to assess a novel formulation of curcumin in a triple transgenic Alzheimer's disease (3xTg‐AD) mouse model and to demonstrate a correlation between Aβ/pTau brain deposition and RGC loss.Methods: 10‐month‐old 3xTg‐AD mice were treated for 3 months with either 0.38 mg/kg intranasal curcumin nanoparticles (CNs) (n = 7) or the equivalent vehicle (n = 6). After 3 months of treatment, animals were imaged using Detection of Apoptosing Retinal Cells (DARC). DARC count was defined as the number of fluorescent spots counted by a masked investigator. After sacrifice, their brains were harvested and immunostained for amyloid‐beta (Aβ) and phosphorylated tau (pTau). Retinas were immunostained with Brn3a, a retinal ganglion cell (RGC) marker. Then, RGC regularity index (RI) was calculated because it is more sensitive than RGC density and declining values of RI are observed during RGC loss and correlate with disease severity.Results: In the brain, CNs were able to reduce Aβ deposition (2.9 ± 0.3 vs 4.4 ± 0.4 Aβ score, p < 0.05) and pTau deposition (1.9 ± 0.7 vs 6.3 ± 1.5 pTau deposition, p < 0.05) compared to the equivalent vehicle. DARC count was reduced with CN treatment compared to vehicle (17.4 ± 3.3 vs 49.1 ± 13.3 DARC spots, p < 0.05). More importantly, CN treatment increased significantly RGC RI compared to vehicle (1.73 ± 0.04 vs 1.58 ± 0.04, p < 0.05) suggesting a neuroprotective effect by reducing RGC loss. Interestingly, DARC count correlated with RGC RI (correlation coefficient ‐0.452, p < 0.05) and Aβ deposition in the brain (correlation coefficient 0.509, p < 0.05).Conclusions: CNs are neuroprotective by reducing Aβ and pTau deposition in the brain and RGC loss. More importantly, DARC can be used to monitor disease activity as it correlates with RGC loss and Aβ deposition in the brain. Further studies are needed to confirm these results.
Read full abstract